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Background: Saliva has been advocated as an alternative to serum or plasma for steroid monitoring. Little
normative information is available concerning expected concentrations of the major reproductive steroids in saliva
during pregnancy and the extended postpartum.
Methods: Matched serum and saliva specimens controlled for time of day and collected less than 30 minutes apart
were obtained in 28 women with normal singleton pregnancies between 32 and 38 weeks of gestation and in 43
women during the first six months postpartum. Concentrations of six steroids (estriol, estradiol, progesterone,
testosterone, cortisol, dehydroepiandrosterone) were quantified in saliva by enzyme immunoassay.
Results: For most of the steroids examined, concentrations in antepartum saliva showed linear increases near end
of gestation, suggesting an increase in the bioavailable hormone component. Observed concentrations were in
agreement with the limited data available from previous reports. Modal concentrations of the ovarian steroids were
undetectable in postpartum saliva and, when detectable in individual women, approximated early follicular phase
values. Only low to moderate correlations between the serum and salivary concentrations were found, suggesting
that during the peripartum period saliva provides information that is not redundant to serum.
Conclusions: Low correlations in the late antepartum may be due to differential rates of change in the total and
bioavailable fractions of the circulating steroid in the final weeks of the third trimester as a consequence of
dynamic changes in carrier proteins such as corticosteroid binding globulin.
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Saliva has been advocated as an alternative to serum or
plasma for the measurement of steroid hormones, and
offers a significant theoretical advantage as a diagnostic
fluid: hormone concentrations in saliva derive primarily
from free steroid present in the general circulation [1-4],
whereas steroid bound to high-affinity binding proteins
such as sex-hormone binding globulin (SHBG) or
corticosteroid-binding globulin (CBG) is present in sal-
iva at levels only ~0.1% of the levels seen in serum or
plasma [5,6]. Accordingly, steroid concentrations in sal-
iva most closely approximate the fraction of the steroid* Correspondence: ehampson@uwo.ca
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reproduction in any medium, provided the orin circulation that is ‘bioavailable’, i.e., that fraction of
the total hormone that is able to exert physiological ef-
fects. The salivary glands contain the enzyme 11β-
hydroxysteroid dehydrogenase II and therefore, for
cortisol, the glands do metabolize some active hor-
mone to cortisone en passant [4]. Even for cortisol,
however, concentrations in saliva have been found to
correlate highly (r = .95 or higher) with the free fraction
measured in serum. At present, there is no simple, accur-
ate, and cost-effective method to isolate this physiologically
important fraction from blood, making saliva an attractive
alternative for many research and clinical applications.
Accurate quantification of hormones in saliva requires
assays with greater sensitivity and precision than those
developed for blood, because under normal conditions
only a small fraction of the steroid (1 - 8%, dependingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lished validity studies examining the correlations be-
tween saliva and serum total or serum free steroid
concentrations are based on radioimmunoassay (RIA)
techniques, but viable non-isotopic methods are starting
to become commercially available for saliva. The fact
that correlations approaching r = 1.0 have been demon-
strated for cortisol, progesterone, testosterone, estriol,
and even estradiol in some studies (e.g., [7-12]; for re-
view see [2,13]) supports the basic validity of salivary
techniques. The magnitude of the correlations, however,
and thus the relative utility of saliva versus blood, can be
influenced by a number of methodological and demo-
graphic variables, not all of which have been identified.
The correlations depend, for instance, on the particular
hormone analyzed, the subject population, type of assay
used, assay parameters such as sensitivity or specificity
of the antiserum, whether saliva is compared with the
free or total fraction in plasma, and adequacy of the sal-
iva collection method. Proper collection and storage are
important [14-16].
Saliva has potential clinical applications in maternal
health monitoring. One impediment to its adoption,
however, is the limited data currently available on the
use of saliva to measure steroids during pregnancy and
the postpartum. Normative data for a range of salivary
steroids during pregnancy are not yet available, espe-
cially for the sex steroids (cf., [17]). Even fewer studies
have examined the correlations between serum and sal-
iva during pregnancy, and thus the viability of saliva as a
substitute for serum determinations. Pregnancy and
post-partum represent the maximal and minimal expected
hormone concentrations that occur in women of repro-
ductive age and may pose a challenge to salivary assays
which generally are optimized to detect differences within
the concentration ranges defined by the menstrual cycle.
Significant changes in carrier proteins, including SHBG
and CBG, also occur during pregnancy and could poten-
tially alter the size of the correlations between serum and
saliva.
Outside of pregnancy, cortisol is considered the best-
validated salivary analyte [18], but estriol is perhaps the best
validated analyte in pregnant women. Salivary monitoring
of estriol concentrations has been suggested as a way to as-
sess fetoplacental function. Early work using RIA reported
an excellent correlation between saliva and either free es-
triol or total estriol in serum (r = 0.98 [8,19,20]; for reports
using enzyme immunoassay (EIA) r = 0.87 [21], r = 0.79
[22]). Pregnancy and the postpartum are characterized by
large changes in cortisol production, CBG levels, and
responsivity of the hypothalamic-pituitary-adrenal axis
[23,24], but scant attention has been paid to serum-saliva
correlations during the reproductive period. Dorn and
Susman [25] found that at ≤ 20 weeks gestation, salivarycortisol showed relatively low correlations with total corti-
sol in serum, ranging from 0.72 to 0.77. Correlations at 2–
3 weeks postpartum were even lower (r = 0.42 to 0.60). It is
unknown whether or not such low correlations are typical
of the postpartum period. These correlations are lower than
those observed for salivary cortisol in many other contexts
(e.g., r = 0.97 [10,26,27]) and, if verified, could conceivably
reflect latent changes in binding proteins during pregnancy.
Lowered correlations between saliva and serum total corti-
sol concentration have been found previously in situations
where there is significant patient-to-patient variation in
CBG levels or in CBG saturation due to medication
use (e.g., oral estrogens) or other factors (e.g., r = 0.67
[28]; r = 0.60 [29]). In such situations the tight linear
association between saliva and the serum unbound
fraction is faithfully preserved [10].
Other salivary steroids have received negligible investi-
gation in the context of pregnancy. Serum estradiol rises
steadily toward term, but the expected concentrations
for salivary estradiol are unknown, as is the serum-saliva
correlation during pregnancy. Changes in SHBG titers
could potentially reduce the correlation between the bio-
available fraction, mirrored in saliva, and total estradiol
as measured in serum. In the postpartum, extremely low
estradiol secretion is a further complication that poses a
technical challenge for accurate quantification. In saliva,
the expected levels of estradiol over the normal men-
strual cycle are in the low picomolar or femtomolar
range and, while satisfactory correlations can be seen under
relatively high estradiol conditions (e.g., in vitro fertilization
with ovarian stimulation, r = 0.86 [30]; r = 0.82 [31]; r = 0.94
[12]), variable correlations have been found over the ordin-
ary menstrual cycle (r = 0.83 [32]; r = 0.93 [33]) with lower
correlations in some studies (r = .60 to .80) reflecting,
among other things, difficulty in establishing satisfactory
assay precision at the low end of the concentration range
(cf., [34]). Technical challenges are likely to be accentuated
in the postpartum. For progesterone, the correlation be-
tween saliva and serum in healthy women typically ranges
from r = 0.80 to 1.0 (r = 0.91 to 0.97 [35]; r = 0.93 [36];
r = 0.84 to 0.89 [37]; r = 0.85 [38]; r = 0.88 [39]; r = 0.98
[7]). Although only limited data are presently available for
progesterone during pregnancy, estimates of the serum-
saliva correlation are inconsistent and differ widely across
studies (e.g., r = 0.46 [40]; r = 0.88 [41]).
Salivary testosterone presents special issues. In men, sal-
ivary testosterone closely mirrors the free fraction of tes-
tosterone in the serum (r = 0.80 to 0.97 [11,42,43]) but in
women, the adequacy of salivary testosterone measures
has been more difficult to establish and correlations
reported are often only moderate in size (e.g., r = 0.55 to
0.85 [11,44-49]). Inadequate antibody specificity or analyt-
ical sensitivities in some studies may potentially explain
the lower correlations, but failure to take availability of
Table 1 Inter- and intra-assay coefficients of variation
and detection limits for the six salivary steroids
Intra CV% Inter CV% Detection limit
Cortisol 3.5 5.1 0.08 nmol/L
Estriol 6.1 7.1 0.06 nmol/L
Estradiol 7.1 7.5 3.65 pmol/L
Progesterone 6.2 7.6 0.02 nmol/L
Testosterone 4.6 9.8 3.47 pmol/L
DHEA 5.6 8.2 0.02 nmol/L
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validation studies have included not just healthy controls
but also women with hirsutism, polycystic ovarian disease,
or obesity, conditions that alter levels of SHBG. Judicious
choice of the serum assay used is important but seldom
considered--many commercial immunoassays for testos-
terone significantly underperform if applied to female
serum [50].
The present study investigated the associations be-
tween salivary and serum measures of six steroids (estra-
diol, estriol, progesterone, testosterone, cortisol, DHEA)
in a group of women who donated paired saliva and
serum specimens during the third trimester of preg-
nancy or the first six postpartum months. This work is a
first step toward establishing the validity of saliva as an
alternative to blood for steroid monitoring during preg-
nancy, and to establishing normative ranges for saliva




Data were available from 28 women tested between 32
and 38 weeks of gestation and 43 women who were
tested between 4 and 16 weeks postpartum (n = 30) or
at 19+ weeks (n = 13). Women were recruited from a
hospital perinatal or obstetric clinic or from local peri-
natal fitness classes, and consented to the collection of
serum and saliva as part of a broad study of mood and
memory in the peripartum, which was approved by the
St. Joseph’s Healthcare Research Ethics Board. The spe-
cific time frames sampled were dictated by the parent
study, as probable times to capture peripartal changes in
mood. Mean age was 30.32 (± 5.05 yr). All pregnancies
were full term and uncomplicated. Most were primipar-
ous (74%). As part of a broader study protocol, the pres-
ence of mood disorders was formally evaluated. Ten
women met DSM-IV criteria for major depression
according to the Mini International Neuropsychiatric
Interview and scored ≥ 11 on the Edinburgh Postnatal
Depression Scale (EPDS). Of the 43 postpartum women,
three met the criteria for depression. All remaining
women were healthy, scored <11 on the EPDS and had
no current or past history of psychiatric or chronic med-
ical conditions or of substance/alcohol use. Oral contra-
ceptive use in the postpartum was screened and data
from one woman were excluded on that basis.
Sample collection
All specimens were collected at a fixed time of day
(1200±2 hrs). Because several of the steroids of interest
show a circadian pattern of release, midday sampling
was chosen as a period of relative stability in the con-
centrations, in order to avoid early morning or eveningsampling when the concentrations of several hormones
undergo rapid changes that could potentially attenuate
the correlations observed between serum and saliva.
Each participant provided one saliva sample and a
matched sample of serum. Saliva was collected via pas-
sive drool into a 15 mL plain polystyrene tube. Partici-
pants were asked to refrain from eating, drinking,
smoking, brushing their teeth, chewing gum or other
oral stimulation for 1 hr prior to sample collection. Par-
ticipants rinsed their mouths, waited 5 min, then do-
nated 3 mL of saliva. The saliva was divided into
separate aliquots and stored at −20°C prior to analysis.
Blood was collected by venipuncture into 10 mL tubes at
St. Joseph’s Hospital outpatient laboratory. After waiting a
minimum of 30 min for coagulation to occur, the tubes
were centrifuged at 3000 rpm for 15 min. The serum was
transferred into 1 mL cryovials (5 aliquots/subject) and
kept at −20°C. All paired serum and saliva samples were
collected within 30 min of each other. The saliva was al-
ways collected first. If, for any reason, the time between
serum and saliva collection extended beyond 30 min, the
results were not included.Saliva immunoassays
Saliva samples were thawed and centrifuged at 3000 rpm
for 15 min, then submitted to assay using batch process-
ing. For each hormone, each patient sample was ana-
lyzed in duplicate using a commercial high-sensitivity
salivary enzyme immunoassay (Salimetrics LLC, an in-
dustry leader in salivary EIAs), following the manufac-
turer’s protocol. Cortisol, estradiol, estriol, progesterone,
testosterone, and DHEA were analyzed. Repeat freeze-
thaw cycles were avoided by using separately frozen ali-
quots for each hormone, which were thawed only as
needed. Although most analytes are stable in saliva for
~5-7 days at room temperature [2,4], the measurement
of some steroids can be altered by bacterial degradation
after as little as 96 hr, even if stored at 4°C [51]. There-
fore, the frozen aliquots were analyzed within only a few
hours of thawing. Samples that exceeded the upper limit
of the standard curve were re-analyzed after dilution.
Table 1 shows the lower limit of detection for the 6 hor-
mones and the intra-assay coefficients of variation.
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Estradiol, free estriol, testosterone, progesterone, and cor-
tisol were assayed in duplicate using the Coat-A-CountW
radioimmunoassay (Diagnostic Products Corporation, Los
Angeles, CA) according to the manufacturer’s instruc-
tions. DHEA was measured using MP Biomedicals DHEA
kit 07D-229102. All hormones were batch processed. All
assays employed a 125I label. Separate aliquots were used,
thereby eliminating freeze-thaw cycles. Any samples that
exceeded the upper limit of the standard curve were re-
analyzed after dilution.
All saliva and serum assays were performed in the Psy-
chiatric Research Laboratory at St. Joseph’s Healthcare
in Hamilton, Ontario. The laboratory has over 10 years
of experience using the Salimetrics kits.
Statistical analysis
Data were analyzed with SPSS v.10 for Windows. Pear-
son correlation coefficients were used to compare the
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Figure 1 Mean salivary steroid concentrations as a function of the nu
between 32 and 38 weeks of gestation. Means are shown according to the
29+ days, n=7/group). Error bars represent the standard error of the mean.Results
Salivary hormone concentrations
Figure 1 shows mean concentrations for all 6 salivary
steroids expressed as a function of the number of days
prior to parturition (for further details, see Table 2).
With the exception of estradiol, the concentrations of all
hormones in saliva were significantly higher during the
3 weeks prior to delivery than at earlier time points.
Polynomial contrasts confirmed a significant linear
trend was present for salivary estriol, F (1, 24) = 9.72,
p = 0.005; progesterone, F (1, 24) = 5.57, p = 0.027; tes-
tosterone, F (1, 24) = 4.90, p = 0.037, DHEA, F (1, 24) =
8.27, p = 0.008; and cortisol concentrations, F (1, 23) =
4.30, p = 0.049. One woman had atypically high estradiol
in her saliva (>1000 pmol/L) at four weeks prior to deliv-
ery and as a result, the linear trend for estradiol was not
significant.
Patient’s depression status did not significantly influ-
ence the levels of any salivary analyte. This remained
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0
mber of days prior to parturition. The women (n = 28) were tested
number of days prior to delivery (< 14 days, 14–21 days, 22–28 days,
Table 2 Salivary steroid concentrations in the antepartum
women by days prior to delivery
Mean ± SEM Median Range
Estriol (nmol/L)
< 14 days 6.37 ± 1.18 6.15 3.37 - 10.11
14-21 days 6.30 ± 0.68 5.92 4.27 - 9.79
22-28 days 4.41 ± 0.58 4.16 2.88 - 7.34
> 28 days 3.61 ± 0.39 3.34 2.21 - 5.12
Estradiol (pmol/L)
< 14 days 447.23 ± 137.51 341 229 - 1128
14-21 days 338.78 ± 65.87 289 67 - 653
22-28 days 373.79 ± 65.39* 376 159 - 558
> 28 days 208.54 ± 27.29 210 116 - 284
Progesterone (nmol/L)
< 14 days 9.28 ± 2.04 8.54 4.30 - 15.92
14-21 days 8.39 ± 1.25 8.10 4.00 - 13.48
22-28 days 5.87 ± 1.25 5.24 1.84 - 11.92
> 28 days 5.18 ± 0.95 5.44 1.76 - 9.74
Testosterone (pmol/L)
< 14 days 418.44 ± 77.17 378 253 - 755
14-21 days 434.54 ± 102.49 354 247 - 1129
22-28 days 270.52 ± 22.65 281 180 - 341
> 28 days 245.68 ± 17.24 257 183 - 301
Cortisol (nmol/L)
< 14 days 12.74 ± 2.32 10.34 7.92 - 22.35
14-21 days 10.96 ± 1.50 9.74 6.41 - 17.75
22-28 days 8.05 ± 0.57 8.50 4.78 - 9.58
> 28 days 8.92 ± 1.28 8.48 5.45 - 12.60
DHEA (nmol/L)
< 14 days 0.52 ± 0.08 0.47 0.28 - 0.85
14-21 days 0.44 ± 0.04 0.39 0.33 - 0.66
22-28 days 0.35 ± 0.06 0.26 0.22 - 0.57
> 28 days 0.32 ± 0.03 0.31 0.23 - 0.44
* = outlier removed, > 1000 pmol/L.
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across all antepartum time points was found to be
slightly lower in depressed than non-depressed
women, F (1, 25) = 3.99, p = 0.057. Salivary cortisol
was slightly higher in the depressed than non-
depressed group after outlier removal, F (1, 25) = 3.47,
p = 0.074, but neither hormone reached the criterion
for significance. Depressed and non-depressed women
did not differ in the timing of their antepartum speci-
men collection, F (1, 26) = 1.22, p = 0.279.
Table 3 shows the median and range of concentrations
found for all 6 salivary steroids in the postpartum. Hor-
monal concentrations were not higher in the women
tested beyond 19 weeks than in those tested between 4and 16 weeks, therefore data are shown in Table 3 for all
women combined. The mean number of weeks postpar-
tum at the time of saliva collection was M = 11.9 and
M = 25.4 wk in the two groups, respectively. For each of
the gonadal steroids, the modal hormone concentration in
the postpartum samples was below the limit of detection
(LOD) of the saliva assays.
Serum hormone concentrations
As expected, serum hormone concentrations rose with
advancing gestational weeks in the usual pattern, but in-
dividual differences in the hormone levels attained were
substantial at all time points with considerable overlap
between the different time points. Although estriol, F
(1, 24) = 5.95, p = 0.022, progesterone, F (1, 24) = 6.35,
p = 0.019, and to a lesser extent estradiol, F (1, 24) =
3.41, p = 0.077 showed a marked increase in serum con-
centration over the final antepartum weeks, this trend was
not significant for DHEA, F (1, 24) = 1.93, p = 0.178, tes-
tosterone, F (1, 24) = 0.64, p = 0.431, or cortisol, F (1, 24) =
0.16, p = 0.691. As in the salivary results, mean serum
estradiol was lower and cortisol was higher among women
who met criteria for antepartum depression, but the differ-
ences were not statistically significant, F (1, 26) = 3.15,
p = 0.088 and F (1, 26) = 2.90, p = 0.101, respectively.
Serum-saliva correlations
Pearson correlations between saliva and serum hormone
concentrations were calculated separately for the ante-
partum and postpartum data (see Table 4). There was no
effect of patient depression status on the correlations
observed between serum and saliva.
In the antepartum, correlations were statistically sig-
nificant but only moderate in size for estradiol, estriol,
and progesterone. For other hormones, the obtained
correlations were low (r = 0.50 or below).
Postpartum, the correlations for all of the gonadal ste-
roids were complicated by the large numbers of speci-
mens falling below the detection threshold of the saliva
assays. Complete data were available only for cortisol
and DHEA (n = 43), and these hormones yielded the
highest correlations (r = 0.60 and 0.65, respectively). A
correlation could not be computed for estriol, as only
one participant had an estriol concentration above
threshold. Table 4 shows the correlation observed for
each hormone (rOBS) based on only those women who
had concentrations above the detectable threshold. Con-
centrations below the detection limit (LOD) of an assay
are considered indeterminate, but if not included when
calculating a correlation, such left-censoring can lead to
a biased estimate of the association [52]. Accordingly,
the same correlations were re-computed so as to include
values below the limit, using 2 alternative data substitu-
tion methods: (i) by assigning a constant value of zero to
Table 3 Salivary steroid concentrations in postpartum women and percentage of samples that yielded detectable
concentrations
Estradiol Estriol Progesterone Testosterone Cortisol DHEA
(pmol/L) (nmol/L) (nmol/L) (pmol/L) (nmol/L) (nmol/L)
Median: 8 ND 0.07 151 3.38 0.39
Mode: ND ND ND ND 1.57 0.68
Range: ND - 28 ND - 0.08 ND - 0.22 ND - 418* 1.57 - 13.47 0.07 - 1.54*
% 81 2 60 81 100 100
ND = not detectable; % = percentage of samples that yielded concentrations falling above the detection limit (LOD) of the assay.
* = outlier removed, > 550 pmol (T) or > 3.50 nmol (DHEA).
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(denoted rZERO in Table 3) or (ii) assigning a value
equal to LOD/√2, as recommended by Hornung and
Reed [53] (rLOD/√2). Regardless of the method used,
Table 4 shows that in the postpartum, the correlation
between serum and salivary measurements was low for
all hormones examined, with no correlation greater
than about 0.60.
Discussion
Saliva has been advocated as an important alternative to
blood for the measurement of gonadal and adrenal ste-
roids. Although the use of tandem mass spectrometry is
increasing for steroid determinations in plasma and can
provide an entire steroid profile in a single analysis, this
technique has received only very limited adoption for
salivary steroids. At present therefore, EIA or conven-
tional RIA remain the major analytic methods in wide-
spread use for salivary sampling. An impediment to the
use of saliva by clinicians is a lack of reliable normative
data regarding the concentration ranges to be expected
under various physiological conditions. Pregnancy and
the postpartum have been particularly understudied.
Using paired serum and saliva specimens, we found that
concentrations of all six steroids in maternal saliva
exhibited a linear increase over the last few weeks of
gestation. The ovarian steroids fell to early follicularTable 4 Correlations between serum and saliva
Antepartum (n = 28) Postpartum (n = 43)
r rOBS rZERO rLOD/√2
Estradiol .71** .41* .62** .59**
Estriol .71** – – –
Progesterone .65** -.06 .48** .40**
Testosterone .48**^ .29^ .59** .62**
Cortisol .30 .60** .60** .60**
DHEA .50** .65**^ .65** .65**
* p < .05, ** p < .01.
^ = outlier removed.
rOBS = observed correlation based only on samples with salivary
concentrations > LOD; rZERO and rLOD/√2 = correlation based on all 43 women
with statistical correction for samples < LOD.values in the extended postpartum. In maternal serum, a
steady increase in steroid concentrations with a peak
near end of term is normally seen over the same time
period [54,55] except for DHEA [54,56] and, in some
studies, testosterone concentrations [54]. Relative to
non-gravid values, DHEA in serum exhibits an increase
that is greatest in the first and second trimesters and a
decrease following parturition which is sustained for sev-
eral months postpartum [56]. Bammann et al. [57] found
that free testosterone, measured by equilibrium dialysis,
was elevated in maternal plasma after gestational week
28 due to increased production rate, lending biological
plausibility to the increase we observed in saliva. Saliva
approximates the biologically active fraction of the circu-
lating hormone [1,3].
Whether or not salivary concentrations increase dur-
ing late gestation and whether any increase is propor-
tional to the increase in total concentrations in serum,
has not been established for most major steroids rele-
vant to maternal physiology. In percentage terms, we ob-
served the largest increases in late gestation for salivary
estradiol and progesterone, while cortisol showed the
smallest percent increase. Salivary cortisol levels resem-
bled those seen using early morning sampling in women
who are not pregnant (14.32 ± 9.1 nmol/L, n = 662,
[58]). Early studies speculated that salivary cortisol may
exhibit no increase during pregnancy in contrast to the
marked rise found in serum, but our observation of
modest elevation is consistent with reports of elevated
basal cortisol late in gestation as measured by either RIA
or EIA [59-61]. The concentrations detected in the
present study were similar to these reports or other re-
cent data [23]. The fact that pregnant women do not
display overt signs of hypercortisolism may be explained
by the relatively modest elevation in the bioavailable
hormone combined with tissue refractoriness to raised
cortisol levels [60,62].
Estriol is detectable in maternal serum in significant
amounts only during pregnancy, when it is synthesized
by the fetoplacental unit from adrenal precursors. Estriol
concentrations rise exponentially in the 2 to 4 weeks be-
fore the onset of spontaneous labour. We found that
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gen in antepartum saliva. Salivary estriol increased
linearly during late gestation and the concentrations
seen at all time points were within expected ranges
based on other studies that have successfully measured
estriol in saliva [19,20,22,63]. Suri et al. [63] used the
Salimetrics EIA, the same EIA employed in the present
work.
Aside from estriol and cortisol, normative data for
other salivary steroids during gestation are significantly
lacking. Available data often are based on a single gesta-
tional time point or else collapsed across large segments
of the third trimester when hormone levels undergo
continuous change, and are therefore difficult to inter-
pret. In contrast to cortisol, by the final two weeks of
gestation we found that progesterone and estradiol were
present in saliva at mean concentrations 30 to 50 times
their values under non-pregnant conditions, suggesting
a substantial change in the bioavailable fraction of these
two steroids. When compared with the limited data
available, the concentrations we observed are similar to
previous reports, both for salivary estradiol [40,64], and
progesterone ([7,40]; but see [65]), although a progres-
sive increase in salivary progesterone in late gestation
was not detected by Lewis, Galvin, and Short [66]. We
also found an increase in salivary testosterone over the
last few weeks of pregnancy. In contrast, Laudat et al.
[67] did not find evidence of increased testosterone rela-
tive to non-pregnant controls in saliva taken as late as
34 to 39 weeks gestation. However, the present data are
consistent with reports that free testosterone in serum is
increased about twofold in the third trimester [57,68].
Ten women in the present sample met DSM-IV cri-
teria for depression during the antepartum. Although
not significant given our sample size, there was a ten-
dency for salivary estradiol to be lower and cortisol to be
higher in women who were depressed. The same pattern
was evident in serum. It would not be entirely surprising
if cortisol levels were elevated in our depressed sub-
group, as a few studies have found elevated cortisol in
saliva [69,70], or urine [71,72] in antepartum depressed
women, particularly women who have comorbid anxiety,
although findings are conflicting [73,74]. Saliva may be a
useful vehicle to study correlations between maternal
hormones and mood because of its theoretical advan-
tages and the practicality of repeat sampling. Further
work is needed to verify the presence of hormonal alter-
ations in antepartum depressed women and to identify
any consequences for fetal development or long-term
outcomes.
Postpartum concentrations also were analyzed. We
found no significant difference in the salivary concentra-
tions measured at 4 to 16 weeks postpartum versus be-
yond 19 weeks. Modal concentrations of the gonadalsteroids fell below the analytical detection limit of the
salivary EIAs in the postpartum. This is consistent with
continuing anovulatory status in most of the women
studied. Only 1–2 women in our dataset showed evi-
dence of ovulatory activity within the study’s timeframe.
Higher concentrations of ovarian steroids would be
expected once menstrual cycling resumed. Only a hand-
ful of published studies have tried to quantify ovarian
steroids in postpartum saliva. For progesterone and es-
tradiol, our median concentrations closely resemble the
three reports available [41,65], which found levels typical
of the early follicular phase of the menstrual cycle at 5
and 6 weeks postpartum, respectively, and at 5 to 20
weeks postpartum [75] (see also [76]). With respect to
estriol, Kundu et al. [8] estimated the estriol concentra-
tion in nongravid saliva to be < 0.11 nmol/L.
Because it contains largely the bioavailable fraction,
expected steroid concentrations in saliva constitute only
a small percentage of the total concentrations found in
serum. Combined with low levels of ovarian activity in
the first few months after delivery, our data suggest the
postpartum period may challenge the detection limits of
many existing salivary EIAs. From the standpoint of clin-
ical chemistry some inevitable loss in assay precision is
to be expected as the true concentrations in saliva ap-
proach the lowermost end of the calibration curve.
Whether the detection of such low levels of hormone is
biologically meaningful is an open question, but bioavail-
ability has been of interest in the study of postpartum
dysphoric mood changes [65]. Until other techniques be-
come widely available, researchers who wish to quantify
bioavailable hormone during the postpartum may need
to utilize customized RIAs that can achieve lowered de-
tection limits, and would be well-advised to collect lar-
ger sample volumes or multiple saliva samples to
facilitate pooling and reduce measurement error attrib-
utable to pulsatile patterns of hormone secretion.
In contrast to the reproductive steroids, the adrenal
corticoids, cortisol and DHEA, were present at quantifi-
able concentrations in the saliva of all women sampled
postpartum. The return of the HPA axis to pregravid
status is time-dependent, but the sensitivity of plasma
cortisol to negative feedback regulation returns to nor-
mal by about 4 to 5 weeks postpartum [60,77]. Median
salivary cortisol in the present study was similar to, or
slightly lower than, the postpartum values seen by Harris
et al. [65] at 6 to 8 weeks, and compare favorably with
the concentrations reported by Tu et al. [75] at 5 to 20
weeks postpartum in primiparous mothers (see also
[59]). Small differences across studies in salivary cortisol
concentrations at matched times of day might reflect,
among other variables, maternal parity.
Although salivary concentrations in the present work
were within typical ranges both ante- and postpartum
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tions we observed between serum and saliva were sub-
stantially below the magnitudes of the correlations for
the same steroids ordinarily seen in non-gravid popula-
tions [13]. Low correspondence between serum and
saliva was evident despite our use of widely utilized
FDA-approved salivary EIAs and acceptable assay quality
(Table 1). For estriol, a body of evidence currently exists
that shows satisfactory correlations between serum and
saliva during gestation (r’s = 0.75 to 0.98), although most
studies have used RIA, not EIA techniques. For other
hormones, there have been almost no published at-
tempts to evaluate paired serum and saliva correlations
in the ante- or postpartum. The low to moderate serum-
saliva correlations in our antepartum data are consistent
with the few existing reports from other labs (estradiol:
r = 0.47-0.60 [40]; progesterone: 0.43-0.46 [40]; r = 0.88
[41]; cortisol: r = 0.55 to 0.77 [25,78]). Sample sizes in
the present study were comparable to or even larger
than most of these reports. One study reported a serum-
saliva correlation of r = 0.92 for progesterone in preg-
nant women [7], but its reliability can be questioned as
the correlation was calculated based on only 9 data
points scattered throughout weeks 5 to 38 of gestation.
Even fewer data currently exist based on postpartum
sampling (progesterone and cortisol: r’s ≈ 0.50 [65]; cor-
tisol: r = 0.42 - 0.60 [25]). Previous studies have used
either mixed longitudinal (e.g., [22,41,78]) or cross-
sectional data collection [7,19,25,40]. Mixed longitudinal
designs have the potential to falsely inflate correlations by
introducing dependencies among pairs of observations
[79], but no obvious differences in the size of the correla-
tions obtained are evident between the studies that have
used cross-sectional vs longitudinal [20] or mixed longitu-
dinal sampling. The low correlations found in the present
work as well as these previous studies suggest that low
correlations between serum and saliva measurements may
not be atypical during late pregnancy and the early
postpartum.
Low to moderate correlations could signify inaccuracies
in the particular EIAs we chose to analyze saliva, but this
seems unlikely given the acceptable performance of these
same assays under other physiological conditions, and the
comparability of the present concentration ranges in ante-
partum saliva to the concentrations identified in previous
work that used either EIA or RIA. Conceivably, small dif-
ferences in antibody specificity between the serum and
saliva assays used here, although insignificant under ordin-
ary circumstances, are amplified in importance under the
high levels of circulating hormones present during late
gestation and lead to reduced correlations to the extent
that cross-reacting analytes change at different rates. EIA
methods have, in fact, been criticized for their sometimes
poor specificities [80]. The Salimetrics reagents used forquantification in the present study, however, have accept-
ably low (i.e., negligible) cross-reactivities with other
major steroids present in antepartum saliva, with one ex-
ception. Indeed, while a correlation of only r = .30 was
found for cortisol during late gestation in the present
study (the lowest correlation we observed), the identical
serum and saliva kits yielded a correlation of r = .96 in a
set of patients screened for Cushing’s syndrome [81]. Al-
though we think it unlikely that differences in antiserum
specificity are responsible for the low correlations ob-
served more generally, such a mechanism might explain
the low correlation seen for testosterone, as the
Salimetrics EIA shows higher cross-reactivity than the
Coat-A-Count method for androstenedione and dihydro-
testosterone [82], hormones that may plausibly be in-
creased antepartum [55].
If not differences in antibody specificity, then what
does account for the low correlations seen? In the post-
partum, the low correlations observed are likely to re-
flect the exceedingly low quantities of bioavailable
hormone associated with ovarian quiescence, the conse-
quent technical difficulty associated with the detection
of such low quantities in saliva, and restriction in the
range of concentration values to be expected in both
serum and saliva, all factors that mitigate against finding
high correlations. Under postpartum conditions, there-
fore, lower correlations are perhaps unsurprising. Low to
moderate correlations seen antepartum are not easily at-
tributed to technical limitations but, in contrast, could
be physiologically significant--they may be a direct con-
sequence of dissociations that occur between the total
and bioavailable fractions in late gestation.
Complex changes in protein binding occur through-
out pregnancy, but especially during the third trimes-
ter. By sequestering active hormone, rising titers of
carrier proteins such as CBG and SHBG in the mater-
nal circulation may serve to protect the mother from
adverse consequences of the rise in fetal production
of steroids [83]. Total concentrations of several ste-
roids in maternal serum increase exponentially near
end of term [55], but our data suggest that increases
in saliva, at least over the timeframe we sampled, are
potentially more linear and display a shallower rate of
increase, consistent with the idea of only limited
change in bioavailable hormone concentrations. We
used a cross-sectional design and it is possible that
increases in saliva concentrations would be sharper if
sampled longitudinally, within an individual woman.
However, serum concentrations in the present study
were compatible with typical normative values for late
gestation, and is it not obvious why any dampening
attributable to the cross-sectional design would affect
only the saliva. When computed across a range of
gestational time points, correlations between serum
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of change in the total vs. bioavailable compartments.
Dissociation between serum and saliva concentrations
may be accentuated near end of term by competition
from other steroids. For example, CBG increases during
gestation, ensuring that unbound levels of cortisol are
only mildly elevated in spite of dramatic increases in
total cortisol concentration in serum. Because progester-
one and cortisol bind to CBG with about equal affinity
[84], the exponential rise in circulating progesterone that
occurs in late gestation competes with cortisol for CBG
binding sites, dynamically affecting the bioavailability of
both hormones. Similarly, the sharp rise in estrogens
near end of gestation may compete with the more mod-
est rise in testosterone for available binding sites on
slower changing quantities of SHBG [55], resulting in
the displacement of some testosterone and increasing
the free concentrations of both hormones. Collectively,
such factors conspire to lower the correlations between
saliva and the total hormone as measured in serum or
plasma. If this hypothesis is correct, the implication is
that serum and salivary assays do not provide redundant
information during pregnancy and potentially may reveal
complementary rather than interchangeable insights into
maternal and fetal health.
Conclusions
Saliva monitoring in pregnancy has the potential to ad-
vance our theoretical understanding of maternal physi-
ology and to inform clinical practice. Some data suggest
that salivary measures may have greater diagnostic rele-
vance and predictive utility than conventional serum or
plasma (e.g., [2,29]) because of the more direct estima-
tion of biologically active hormone offered by saliva. Our
study is among the first to investigate a range of salivary
steroids during the third trimester and extended post-
partum, and may help to address a significant gap in
current literature by contributing toward the establish-
ment of normative reference ranges for the salivary ste-
roids examined. It will be desirable for future work to
collect saliva from individual women at multiple time
points during the late antepartum to verify the salivary
profiles found in the present study. Low correlations be-
tween paired serum and saliva specimens collected less
than 30 minutes apart suggest the two media may index
different but overlapping fractions of the hormone
present in the maternal circulation.
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